vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and AEye, Inc. (LIDR). Click either name above to swap in a different company.
AEye, Inc. is the larger business by last-quarter revenue ($188.0K vs $115.4K, roughly 1.6× CytoMed Therapeutics Ltd). CytoMed Therapeutics Ltd produced more free cash flow last quarter ($-855.4K vs $-9.7M).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
AEye, Inc. develops and manufactures high-performance adaptive lidar perception systems for multiple commercial sectors. Its core products are deployed in advanced driver assistance systems, autonomous passenger and commercial vehicles, industrial robotics, smart infrastructure, and logistics automation, serving global automotive, technology and industrial clients.
GDTC vs LIDR — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2023
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $188.0K |
| Net Profit | — | $-17.0M |
| Gross Margin | — | -2282.4% |
| Operating Margin | — | -9167.6% |
| Net Margin | — | -9068.1% |
| Revenue YoY | — | -75.5% |
| Net Profit YoY | — | 27.8% |
| EPS (diluted) | — | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $115.4K | — | ||
| Q3 23 | — | $188.0K | ||
| Q2 23 | — | $571.0K | ||
| Q1 23 | — | $636.0K | ||
| Q4 22 | — | $1.1M | ||
| Q3 22 | — | $767.0K | ||
| Q2 22 | — | $706.0K | ||
| Q1 22 | — | $1.1M |
| Q2 25 | — | — | ||
| Q3 23 | — | $-17.0M | ||
| Q2 23 | — | $-16.0M | ||
| Q1 23 | — | $-26.3M | ||
| Q4 22 | — | $-23.7M | ||
| Q3 22 | — | $-23.6M | ||
| Q2 22 | — | $-26.5M | ||
| Q1 22 | — | $-24.9M |
| Q2 25 | — | — | ||
| Q3 23 | — | -2282.4% | ||
| Q2 23 | — | -234.7% | ||
| Q1 23 | — | -255.5% | ||
| Q4 22 | — | -185.3% | ||
| Q3 22 | — | -253.1% | ||
| Q2 22 | — | -102.1% | ||
| Q1 22 | — | -37.0% |
| Q2 25 | — | — | ||
| Q3 23 | — | -9167.6% | ||
| Q2 23 | — | -2834.7% | ||
| Q1 23 | — | -4070.6% | ||
| Q4 22 | — | -2195.9% | ||
| Q3 22 | — | -3034.4% | ||
| Q2 22 | — | -3772.4% | ||
| Q1 22 | — | -2303.3% |
| Q2 25 | — | — | ||
| Q3 23 | — | -9068.1% | ||
| Q2 23 | — | -2807.5% | ||
| Q1 23 | — | -4129.7% | ||
| Q4 22 | — | -2174.2% | ||
| Q3 22 | — | -3080.1% | ||
| Q2 22 | — | -3748.9% | ||
| Q1 22 | — | -2299.5% |
| Q2 25 | — | — | ||
| Q3 23 | — | $-0.09 | ||
| Q2 23 | — | $-0.09 | ||
| Q1 23 | — | $-4.75 | ||
| Q4 22 | — | $-18.34 | ||
| Q3 22 | — | $-0.15 | ||
| Q2 22 | — | $-0.17 | ||
| Q1 22 | — | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $37.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $53.3M |
| Total Assets | — | $80.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | — | ||
| Q3 23 | — | $37.1M | ||
| Q2 23 | — | $18.4M | ||
| Q1 23 | — | $20.5M | ||
| Q4 22 | — | $19.1M | ||
| Q3 22 | — | $58.5M | ||
| Q2 22 | — | $4.2M | ||
| Q1 22 | — | $11.2M |
| Q2 25 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | $0 | ||
| Q3 22 | — | $0 | ||
| Q2 22 | — | $0 | ||
| Q1 22 | — | $0 |
| Q2 25 | — | — | ||
| Q3 23 | — | $53.3M | ||
| Q2 23 | — | $65.7M | ||
| Q1 23 | — | $76.0M | ||
| Q4 22 | — | $94.0M | ||
| Q3 22 | — | $111.0M | ||
| Q2 22 | — | $127.6M | ||
| Q1 22 | — | $147.2M |
| Q2 25 | — | — | ||
| Q3 23 | — | $80.9M | ||
| Q2 23 | — | $95.9M | ||
| Q1 23 | — | $110.1M | ||
| Q4 22 | — | $133.3M | ||
| Q3 22 | — | $150.7M | ||
| Q2 22 | — | $161.3M | ||
| Q1 22 | — | $177.8M |
| Q2 25 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | 0.00× | ||
| Q3 22 | — | 0.00× | ||
| Q2 22 | — | 0.00× | ||
| Q1 22 | — | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | $-9.1M |
| Free Cash FlowOCF − Capex | $-855.4K | $-9.7M |
| FCF MarginFCF / Revenue | -741.5% | -5146.8% |
| Capex IntensityCapex / Revenue | 0.0% | 326.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-59.9M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-855.3K | — | ||
| Q3 23 | — | $-9.1M | ||
| Q2 23 | — | $-15.3M | ||
| Q1 23 | — | $-17.2M | ||
| Q4 22 | — | $-16.1M | ||
| Q3 22 | — | $-22.4M | ||
| Q2 22 | — | $-17.1M | ||
| Q1 22 | — | $-16.0M |
| Q2 25 | $-855.4K | — | ||
| Q3 23 | — | $-9.7M | ||
| Q2 23 | — | $-15.5M | ||
| Q1 23 | — | $-17.8M | ||
| Q4 22 | — | $-16.9M | ||
| Q3 22 | — | $-24.1M | ||
| Q2 22 | — | $-18.1M | ||
| Q1 22 | — | $-16.8M |
| Q2 25 | -741.5% | — | ||
| Q3 23 | — | -5146.8% | ||
| Q2 23 | — | -2707.4% | ||
| Q1 23 | — | -2797.8% | ||
| Q4 22 | — | -1549.6% | ||
| Q3 22 | — | -3136.4% | ||
| Q2 22 | — | -2560.1% | ||
| Q1 22 | — | -1552.4% |
| Q2 25 | 0.0% | — | ||
| Q3 23 | — | 326.1% | ||
| Q2 23 | — | 36.6% | ||
| Q1 23 | — | 94.2% | ||
| Q4 22 | — | 73.1% | ||
| Q3 22 | — | 214.2% | ||
| Q2 22 | — | 139.5% | ||
| Q1 22 | — | 71.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
